Williams Jones Wealth Management LLC. Buys 134,470 Shares of Quanterix Co. (NASDAQ:QTRX)

Williams Jones Wealth Management LLC. boosted its position in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 39.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 471,514 shares of the company's stock after purchasing an additional 134,470 shares during the period. Williams Jones Wealth Management LLC. owned about 1.22% of Quanterix worth $5,012,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of QTRX. Ameriprise Financial Inc. grew its holdings in shares of Quanterix by 111.3% in the 4th quarter. Ameriprise Financial Inc. now owns 3,205,928 shares of the company's stock valued at $34,079,000 after acquiring an additional 1,688,680 shares in the last quarter. Portolan Capital Management LLC boosted its position in Quanterix by 2.7% during the fourth quarter. Portolan Capital Management LLC now owns 2,587,824 shares of the company's stock valued at $27,509,000 after purchasing an additional 67,138 shares during the last quarter. Vanguard Group Inc. boosted its position in Quanterix by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,217,225 shares of the company's stock valued at $23,569,000 after purchasing an additional 19,386 shares during the last quarter. Millennium Management LLC grew its stake in Quanterix by 6.0% in the fourth quarter. Millennium Management LLC now owns 2,185,101 shares of the company's stock valued at $23,228,000 after purchasing an additional 122,969 shares in the last quarter. Finally, William Blair Investment Management LLC acquired a new position in shares of Quanterix during the 4th quarter worth approximately $11,290,000. Institutional investors and hedge funds own 86.48% of the company's stock.

Quanterix Trading Up 0.4%

Shares of NASDAQ:QTRX traded up $0.02 during trading on Monday, reaching $4.85. 409,846 shares of the stock were exchanged, compared to its average volume of 573,581. The firm has a market cap of $188.32 million, a PE ratio of -4.58 and a beta of 1.12. Quanterix Co. has a 12 month low of $4.05 and a 12 month high of $19.18. The stock has a 50-day moving average price of $5.64 and a 200-day moving average price of $8.44.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.16. The business had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, sell-side analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

QTRX has been the subject of several recent analyst reports. Scotiabank reissued an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a research report on Thursday. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 target price (down from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Leerink Partnrs lowered Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group decreased their target price on Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Quanterix has a consensus rating of "Hold" and a consensus target price of $15.60.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.